文献速递流行病学与生物统计临床试验与 GCP

平台试验的方法学与设计:一项元流行病学研究

Methodology and design of platform trials: a meta-epidemiological study.
PubMed 文献 · J Clin Epidemiol · 2023-03-08

该研究系统检索2015年1月至2022年1月EMBASE、MEDLINE、CENTRAL和clinicaltrials.gov,纳入98项随机平台试验,总结其方法学与设计特征。多数平台试验(68.3%)在2020至2022年注册,与COVID-19大流行重合;28.6%使用贝叶斯方法,66.3%使用频率学方法。

要点

  • 共纳入98项随机平台试验,68.3%在2020至2022年注册。
  • 28.6%的平台试验使用贝叶斯方法,66.3%使用频率学方法。
  • 25项有同行评议发表结果的试验中,7项使用贝叶斯方法,其中100%报告了获益阈值。

核心结论

  • 该研究识别并总结了平台试验的关键组成部分,包括方法学和统计学考虑的基本要点。
  • 作者认为,改善平台试验的标准化和报告需要了解当前现状,并提供了迄今为止最新且严谨的平台试验综述。

研究设计与样本

  • 系统综述,检索EMBASE、MEDLINE、Cochrane对照试验中心注册库(CENTRAL)和clinicaltrials.gov,检索时间为2015年1月至2022年1月,纳入平台试验的方案或结果。
  • 由两名评价者独立、重复收集试验注册、方案和发表资料中的试验特征数据。
  • 结果以总数和百分比报告,适当时以中位数和四分位距(IQR)报告。
  • 共识别98项独特的随机平台试验。

主要发现

  • 共识别15,277条独特检索记录,去除重复后筛选14,403条标题和摘要。
  • 98项平台试验中,16项来源于2019年完成的一项系统综述,该系统综述纳入2015年之前报告的平台试验。
  • 多数平台试验(n=67,68.3%)在2020至2022年注册,与COVID-19大流行重合。
  • 纳入的平台试验主要从北美或欧洲招募或计划招募患者,多数受试者来自美国(n=39,39.7%)和英国(n=31,31.6%)。
  • 28.6%(n=28)的平台随机对照试验使用贝叶斯方法,66.3%(n=65)使用频率学方法,其中1项(1%)同时使用两种范式的方法。

关键数值与推荐

  • 25项有同行评议发表结果的试验中,7项(28%)使用贝叶斯方法,其中2项(8%)使用预定义样本量计算,其余使用在预设间隔计算的预设无效、伤害或获益概率来指导停止干预或整个试验的决策。
  • 17项(68%)同行评议发表使用频率学方法。
  • 7项已发表的贝叶斯试验中,7项(100%)报告了获益阈值。
  • 获益阈值范围为80%至>99%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Adaptive platforms allow for the evaluation of multiple interventions at a lower cost and have been growing in popularity, especially during the COVID-19 pandemic. The objective of this review is to summarize published platform trials, examine specific methodological design features among these studies, and hopefully aid readers in the evaluation and interpretation of platform trial results. METHODS: We performed a systematic review of EMBASE, MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and clinicaltrials.gov from January 2015 to January 2022 for protocols or results of platform trials. Pairs of reviewers, working independently and in duplicate, collected data on trial characteristics of trial registrations, protocols, and publications of platform trials. We reported our results using total numbers and percentages, as well as medians with interquartile range (IQR) when appropriate. RESULTS: We identified 15,277 unique search records and screened 14,403 titles and abstracts after duplicates were removed. We identified 98 unique randomized platform trials. Sixteen platform trials were sourced from a systematic review completed in 2019, which included platform trials reported prior to 2015. Most platform trials (n = 67, 68.3%) were registered between 2020 and 2022, coinciding with the COVID-19 pandemic. The included platform trials primarily recruited or plan to recruit patients from North America or Europe, with most subjects being recruited from the United States (n = 39, 39.7%) and the United Kingdom (n = 31, 31.6%). Bayesian methods were used in 28.6% (n = 28) of platform RCTs and frequentist methods in 66.3% (n = 65) of trials, including 1 (1%) that used methods from both paradigms. Out of the twenty-five trials with peer-reviewed publication of results, seven trials used Bayesian methods (28%), and of those, two (8%) used a predefined sample size calculation while the remainder used pre-specified probabilities of futility, harm, or benefit calculated at (pre-specified) intervals to inform decisions about stopping interventions or the entire trial. Seventeen (68%) peer-reviewed publications used frequentist methods. Out of the seven published Bayesian trials, seven (100%) reported thresholds for benefit. The threshold for benefit ranged from 80% to >99%. CONCLUSION: We identified and summarized key components of platform trials, including the basics of the methodological and statistical considerations. Ultimately, improving standardization and reporting in platform trials require an understanding of the current landscape. We provide the most updated and rigorous review of platform trials to date.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Pitre T, Cheng S, Cusano E, et al. Methodology and design of platform trials: a meta-epidemiological study. J Clin Epidemiol. 2023. PMID: 36893990. doi:10.1016/j.jclinepi.2023.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。